CTOs on the Move


 
Listening to your body is one thing, understanding what it is telling you is an altogether different story. Polar helps you get under the skin of your training. We put it down to a combination of expertise in sports, physiology and electronics, coupled with a deep understanding of customer needs. It`s no surprise then that we`ve been leading the way in technological innovations and heart rate monitors since 1977. And we cater for all levels of fitness by offering a comprehensive product range, along with essential support and advice. Everything from improving an athlete`s sports performance to helping people enjoy a ...
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.polar.com
  • 1111 Marcus Avenue Suite M15
    Lake Success, NY USA 11042
  • Phone: 516.355.7910

Executives

Name Title Contact Details

Similar Companies

Amino

Amino, the leading healthcare guidance platform, connects people with high-quality, cost-effective providers and benefits programs in context across the healthcare ecosystem. With more than 17B healthcare claims used to inform our actionable healthcare recommendations, Amino reduces wasteful claims spending, streamlines care routing, increases care quality, and improves member experience.

Abbiotec

Abbiotec is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NM Dept. of Health

The mission of New Mexico Department of Health is to promote health and wellness, improve health outcomes, and assure safety net services for all people in New Mexico.

Elkhart Clinic, LLC

Elkhart Clinic, LLC is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Elkhart, IN. To find more information about Elkhart Clinic, LLC, please visit www.elkhartclinic.com

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.